Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The company’s lead product, RELiZORB®, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The company’s platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by top-tier venture investors Athyrium Capital Management, Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures.
Location: United States, Texas
Employees: 11-50
Total raised: $79M
Founded date: 2011
Investors 4
| Date | Name | Website |
| 14.03.2024 | Linden Cap... | lindenllc.... |
| - | HealthQues... | healthques... |
| 25.12.2021 | Bessemer V... | bvp.com |
| - | Frazier Li... | frazierls.... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 27.02.2020 | - | $10M | - |
| 17.06.2016 | - | $49M | - |
| 22.07.2013 | Series B | $10M | - |
| 17.04.2012 | Series A | $10M | - |
Mentions in press and media 10
| Date | Title | Description | Source |
| 12.03.2024 | Linden Invests in Alcresta Therapeutics | Chicago, IL (March 12, 2024) – Linden Capital Partners (“Linden”), a Chicago-based healthcare privat... | lindenllc.... |
| 12.03.2024 | Linden Capital Partners Acquires Alcresta Therapeutics, Inc. | CHICAGO and WALTHAM, Mass., March 12, 2024 /PRNewswire/ -- Linden Capital Partners ("Linden&quo... | salamancap... |
| 01.12.2017 | CVS and Amazon battle to own the health care consumer | Two reports have set the healthcare community abuzz this week. The first uncovered that CVS is consi... | venturebea... |
| 17.06.2016 | UPDATED: Alcresta raises $49M for digestive enzyme launch | Alcresta has raised $49.4 million in a Series C financing to support the launch of its novel digesti... | fiercebiot... |
| 22.07.2013 | Alcresta Secures $10M Series B | NEWTON, MA, Leading medical nutrition company developing innovative enzyme-based products for adul... | vcnewsdail... |
| 22.07.2013 | Alcresta Secures $10 Million Series B Financing, Prepares fo... | Alcresta Secures $10 Million Series B Financing, Prepares for 2014 Commercial Launch of Novel Point-... | fiercebiot... |
| 22.07.2013 | Alcresta Raises $10M in Series B Financing | Alcresta, a Newton, MA-based medical nutrition company developing innovative enzyme-based products f... | finsmes.co... |
| 17.04.2012 | Alcresta Secures $10M Series A | NEWTON, MA, Company developing innovative enzyme-based nutritional products for infants, adults an... | vcnewsdail... |
| 17.04.2012 | Alcresta Raises $10M in Series A Financing | Alcresta, a Newton, Mass.-based company developing innovative enzyme-based nutritional products for ... | finsmes.co... |
| - | John Collison on Stripe’s growth plans, the obsession over a... | Before you ask, no, I have no idea when or if Stripe is going public. And, to his credit, John Colli... | fortune.co... |